#United States #Intensity Therapeutics #Shelton #Nasdaq Compliance #Intratumoral Cancer Therapies

Intensity Therapeutics, Inc. Reestablishes Nasdaq Compliance

Shelton, Conn., August 12, 2025 – In a significant milestone for the company, Intensity Therapeutics, Inc. (Nasdaq: INTS), a leading late-stage clinical biotechnology firm, has received confirmation of its compliance with the Nasdaq Stock Market's minimum stockholders' equity requirement. This development positions the company favorably as it continues its groundbreaking work in cancer therapy.

Meeting Nasdaq's Standards

On August 7, 2025, Intensity Therapeutics submitted its Quarterly Report on Form 10-Q for the second quarter ending June 30, 2025. The report outlined the company's financial position, indicating a healthy stockholder equity balance that totaled at least $2,500,000. Following this submission, the Nasdaq Listing Qualifications Staff affirmed on August 8, 2025, that Intensity had regained its compliance with the stockholders' equity requirement, which is critical for sustained trading on the exchange.

Intensity’s President and CEO, Lewis H. Bender, expressed satisfaction with this achievement, linking it directly to the company's successful fundraising efforts through July 2025. “We are pleased with regaining compliance with the minimum stockholders' equity requirement based on our positive fundraising efforts through the end of July 2025,” he stated. “Looking ahead, we estimate having sufficient capital to support our operational plans well into the second half of 2026.”

Innovative Cancer Therapies

At the forefront of Intensity's initiatives is INT230-6, its leading investigational treatment for various cancers that utilizes a unique direct intratumoral injection methodology. This approach leverages two potent anti-cancer agents, cisplatin and vinblastine sulfate, along with a novel molecule known as “SHAO” that enhances drug diffusion within tumors. This strategy is designed not only to eradicate tumor cells but also to stimulate a systemic immune response against cancer without the side effects typically associated with traditional chemotherapy.

The design of INT230-6 reflects the company’s commitment to innovative solutions in oncology. By enabling effective drug dispersion within a tumor’s dense environment, the treatment has demonstrated the potential to elicit immune responses within days of administration, marking a promising shift in cancer treatment paradigms. According to clinical data, Intensity’s approach could convert many high-risk cancers into manageable, chronic conditions.

Clinical Trials and Future Endeavors

Intensity has undertaken two clinical trials involving over 200 participants, focusing extensively on the treatment's effectiveness in metastatic cancers and locally advanced breast cancer. Notably, the Phase 2 randomized control trial for locally advanced breast cancer, known as the INVINCIBLE-2 Study, assesses the impact of INT230-6 in patients not previously subjected to chemotherapy. The company is advancing with a Phase 3 trial for soft tissue sarcoma and a collaborative study with the Swiss Cancer Group aimed at evaluating INT230-6 alongside standard of care treatments for triple-negative breast cancer.

The promising data from these studies underline the transformative potential of Intensity Therapeutics’ innovations in cancer treatment—developments that continue to attract attention within the medical and scientific communities. As the company progresses, its dedication to pioneering research and groundbreaking therapies remains steadfast, with the aim of enhancing patient outcomes in oncology.

Conclusion

With its recent compliance assurance from Nasdaq and an innovative product pipeline, Intensity Therapeutics, Inc. stands at a pivotal moment in its journey. As the company works toward redefining cancer therapy and establishing itself as a leader in this critical field of healthcare, it continues to rely on strategic funding and clinical insights to propel forward. Interested parties can access more information and updates on the company's groundbreaking approaches at www.intensitytherapeutics.com.

Forward-Looking Statements: This article includes forward-looking statements about future business plans and may contain risks and uncertainties. Readers are urged not to place undue reliance on these statements.